Kuhnil about to acquire approval of world’s first children sleep medication
On the 23rd of November, Kuhnil Pharm(CEO Young-Joong Kim, Jae-Hee Choi) announced it was informed the Phase 3 clinical trial of Circadilly that will be introduced from Israeli Neurim was successfully completed.
Circadilly that is recently completed in the Phase 3 clinical trial is a product tha...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
